Molecular Imaging of Prostate Cancer.
暂无分享,去创建一个
[1] M. Stampfer,et al. The high prevalence of undiagnosed prostate cancer at autopsy: implications for epidemiology and treatment of prostate cancer in the Prostate‐specific Antigen‐era , 2015, International journal of cancer.
[2] F. Mottaghy,et al. [68Ga]PSMA-HBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical practice , 2015, European Journal of Nuclear Medicine and Molecular Imaging.
[3] Y. Fujibayashi,et al. Acetate/acetyl-CoA metabolism associated with cancer fatty acid synthesis: overview and application. , 2015, Cancer letters.
[4] P. Choyke,et al. Anti-1-Amino-3-F-18-Fluorocyclobutane-1-Carboxylic Acid: Physiologic Uptake Patterns, Incidental Findings, and Variants That May Simulate Disease , 2014 .
[5] S. Groshen,et al. Comparative performance of PET tracers in biochemical recurrence of prostate cancer: a critical analysis of literature. , 2014, American journal of nuclear medicine and molecular imaging.
[6] K. Partanen,et al. Preliminary Clinical Experience of trans-1-Amino-3-(18)F-fluorocyclobutanecarboxylic Acid (anti-(18)F-FACBC) PET/CT Imaging in Prostate Cancer Patients , 2014, BioMed research international.
[7] Osman Ratib,et al. Potential of hybrid 18F-fluorocholine PET/MRI for prostate cancer imaging , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[8] Serge K. Lyashchenko,et al. A prospective pilot study of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy. , 2014, The Journal of urology.
[9] V. Ambrosini,et al. 18F-FACBC compared with 11C-choline PET/CT in patients with biochemical relapse after radical prostatectomy: a prospective study in 28 patients. , 2014, Clinical genitourinary cancer.
[10] S. Larson,et al. Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival. , 2014, Radiology.
[11] K. Kairemo,et al. Meta-analysis of 11C-choline and 18F-choline PET/CT for management of patients with prostate cancer , 2014, Nuclear medicine communications.
[12] Jurgen J Fütterer,et al. Accuracy of multiparametric MRI for prostate cancer detection: a meta-analysis. , 2014, AJR. American journal of roentgenology.
[13] Stavroula Sofou,et al. Anti–Prostate-Specific Membrane Antigen Liposomes Loaded with 225Ac for Potential Targeted Antivascular α-Particle Therapy of Cancer , 2014, The Journal of Nuclear Medicine.
[14] S. Ramin,et al. Application of 11C‐acetate positron‐emission tomography (PET) imaging in prostate cancer: systematic review and meta‐analysis of the literature , 2013, BJU international.
[15] M. Gleave,et al. Targeting amino acid transport in metastatic castration-resistant prostate cancer: effects on cell cycle, cell growth, and tumor development. , 2013, Journal of the National Cancer Institute.
[16] F. M. van der Zant,et al. A literature review of 18F-fluoride PET/CT and 18F-choline or 11C-choline PET/CT for detection of bone metastases in patients with prostate cancer , 2013, Nuclear medicine communications.
[17] T. Holland-Letz,et al. Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer , 2013, European Journal of Nuclear Medicine and Molecular Imaging.
[18] S. Larson,et al. Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] I. Jambor,et al. In Vivo Imaging of Prostate Cancer Using [68Ga]-Labeled Bombesin Analog BAY86-7548 , 2013, Clinical Cancer Research.
[20] S. Groshen,et al. Baseline 18F-FDG PET/CT Parameters as Imaging Biomarkers of Overall Survival in Castrate-Resistant Metastatic Prostate Cancer , 2013, The Journal of Nuclear Medicine.
[21] E. Mazaris,et al. Molecular Pathways in Prostate Cancer , 2013, Nephro-urology monthly.
[22] P. Muzzio,et al. Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high-risk prostate cancer: a systematic literature review and meta-analysis. , 2013, European urology.
[23] Stanley J. Goldsmith,et al. Phase II Study of Lutetium-177–Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer , 2013, Clinical Cancer Research.
[24] D. Rubello,et al. Choline PET or PET/CT and Biochemical Relapse of Prostate Cancer: A Systematic Review and Meta-Analysis , 2013, Clinical nuclear medicine.
[25] F. Mottaghy,et al. Evaluation of androgen-induced effects on the uptake of [18F]FDG, [11C]choline and [11C]acetate in an androgen-sensitive and androgen-independent prostate cancer xenograft model , 2013, EJNMMI Research.
[26] J. Chen,et al. Role of magnetic resonance imaging in the detection of local prostate cancer recurrence after external beam radiotherapy and radical prostatectomy. , 2013, Clinical oncology (Royal College of Radiologists (Great Britain)).
[27] J. Reubi,et al. Targeting GRPR in urological cancers—from basic research to clinical application , 2013, Nature Reviews Urology.
[28] J. Sörensen,et al. Whole-body diffusion-weighted MRI compared with (18)F-NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinoma. , 2012, AJR. American journal of roentgenology.
[29] D. Amadori,et al. Perspectives on mTOR inhibitors for castration-refractory prostate cancer. , 2012, Current cancer drug targets.
[30] M. Honer,et al. Evolution of Bombesin Conjugates for Targeted PET Imaging of Tumors , 2012, PloS one.
[31] Laurence Collette,et al. Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? , 2012, European urology.
[32] P. Choyke,et al. 11C-Acetate PET/CT in Localized Prostate Cancer: A Study with MRI and Histopathologic Correlation , 2012, The Journal of Nuclear Medicine.
[33] C. Catalano,et al. Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP). , 2012, European journal of radiology.
[34] C. Calaminus,et al. Assessment of PET Tracer Uptake in Hormone-Independent and Hormone-Dependent Xenograft Prostate Cancer Mouse Models , 2011, The Journal of Nuclear Medicine.
[35] C. Kao,et al. Androgen-independent molecular imaging vectors to detect castration-resistant and metastatic prostate cancer. , 2011, Cancer research.
[36] G. Bauman,et al. 18F-fluorocholine for prostate cancer imaging: a systematic review of the literature , 2011, Prostate Cancer and Prostatic Diseases.
[37] W. Weber,et al. Evaluation of the GRPR radioantagonist Cu-64-CB-TE2A-AR-06 in mice and men , 2011 .
[38] N. Satyamurthy,et al. In Vivo Imaging of Intraprostatic-Specific Gene Transcription by PET , 2011, The Journal of Nuclear Medicine.
[39] D. Mankoff,et al. C11-Acetate and F-18 FDG PET for Men With Prostate Cancer Bone Metastases: Relative Findings and Response to Therapy , 2011, Clinical nuclear medicine.
[40] P. Waldenberger,et al. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. , 2010, Radiology.
[41] Y. Fujibayashi,et al. Tumor uptake of radiolabeled acetate reflects the expression of cytosolic acetyl-CoA synthetase: implications for the mechanism of acetate PET. , 2009, Nuclear medicine and biology.
[42] Mijin Yun,et al. The Importance of Acetyl Coenzyme A Synthetase for 11C-Acetate Uptake and Cell Survival in Hepatocellular Carcinoma , 2009, Journal of Nuclear Medicine.
[43] E. Adang,et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. , 2008, Clinical radiology.
[44] S. Gambhir,et al. Configurations of a two-tiered amplified gene expression system in adenoviral vectors designed to improve the specificity of in vivo prostate cancer imaging , 2008, Gene Therapy.
[45] S. Kridel,et al. 1-11C-Acetate as a PET Radiopharmaceutical for Imaging Fatty Acid Synthase Expression in Prostate Cancer , 2008, Journal of Nuclear Medicine.
[46] S. Kohlfuerst,et al. The value of 18F-Choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[47] O. Muzik,et al. Tumor Imaging Using 1-(2′-deoxy-2′-18F- Fluoro-β-d-Arabinofuranosyl)Thymine and PET , 2007, Journal of Nuclear Medicine.
[48] Aditya Bansal,et al. Effect of hypoxia on the uptake of [methyl-3H]choline, [1-14C] acetate and [18F]FDG in cultured prostate cancer cells. , 2006, Nuclear medicine and biology.
[49] G. Lenoir,et al. Acetyl-CoA Carboxylase α Is Essential to Breast Cancer Cell Survival , 2006 .
[50] C. Supuran,et al. Skewing towards neuroendocrine phenotype in high grade or high stage androgen-responsive primary prostate cancer. , 2005, European urology.
[51] C. Dence,et al. Positron tomographic assessment of androgen receptors in prostatic carcinoma , 2005, European Journal of Nuclear Medicine and Molecular Imaging.
[52] G. Jakse,et al. Expression of glucose transporter 1 (Glut-1) in cell lines and clinical specimens from human prostate adenocarcinoma. , 2004, Anticancer research.
[53] Prabhjot Kaur,et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[54] G. D. Vincentis,et al. 99mTc-bombesin detects prostate cancer and invasion of pelvic lymph nodes , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[55] F Fazio,et al. Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography. , 2003, The Journal of urology.
[56] Nobuyuki Oyama,et al. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[57] Jose M. Silva,et al. Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy , 2002, Oncogene.
[58] D. Epner,et al. Methionine restriction induces apoptosis of prostate cancer cells via the c-Jun N-terminal kinase-mediated signaling pathway. , 2002, Cancer letters.
[59] J. Humm,et al. Differential Metabolism and Pharmacokinetics of L-[1-(11)C]-Methionine and 2-[(18)F] Fluoro-2-deoxy-D-glucose (FDG) in Androgen Independent Prostate Cancer. , 1999, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.
[60] D. Bostwick,et al. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. , 1998, Urology.
[61] M. Bergström,et al. Positron emission tomography (PET) with 11C-5-hydroxytryptophan (5-HTP) in patients with metastatic hormone-refractory prostatic adenocarcinoma. , 1997, Nuclear medicine and biology.
[62] W. Fair,et al. Expression of the prostate-specific membrane antigen. , 1994, Cancer research.
[63] J. Clarhaut,et al. Serotonin and cancer: what is the link? , 2015, Current molecular medicine.
[64] V. Ambrosini,et al. Is there a role for 11C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml? , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[65] O. Muzik,et al. Imaging DNA synthesis with [18F]FMAU and positron emission tomography in patients with cancer , 2004, European Journal of Nuclear Medicine and Molecular Imaging.
[66] Mithat Gonen,et al. Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.